Mode
Text Size
Log in / Sign up

Transcriptomic meta-analysis in bipolar disorder identifies mitochondrial, synaptic, and inflammatory pathway genes

Transcriptomic meta-analysis in bipolar disorder identifies mitochondrial, synaptic, and inflammator…
Photo by Artfox Photography / Unsplash
Key Takeaway
Consider mitochondrial, synaptic, and inflammatory gene pathways as research targets in bipolar disorder.

This meta-analysis integrated publicly available transcriptomic datasets from 917 postmortem brain samples (386 bipolar disorder patients, 531 controls) and 638 peripheral blood samples (316 BD patients, 322 controls). The analysis aimed to identify differentially expressed genes (DEGs) across brain and blood in BD. No specific intervention or exposure was studied; the comparator was control samples from individuals without BD.

The main results showed enrichment of genes involved in mitochondrial bioenergetics and oxidative stress, synaptic structure, signaling, and neuroinflammatory pathways. The analysis also identified several novel long non-coding RNAs, microRNAs, and small nucleolar RNAs not previously linked to BD, including SNORD62B, SNORA70, and SNORA10. DrugBank annotation highlighted pharmacologically actionable genes such as SST, P2RY12, and C3. No effect sizes, absolute numbers, p-values, or confidence intervals were reported for these findings.

Safety and tolerability data were not reported, as this was an analysis of transcriptomic data. Key limitations were not explicitly stated in the input. The practice relevance is restrained: this meta-analysis provides candidate biomarkers and druggable targets (e.g., SST) to guide future mechanistic and therapeutic studies. The findings are associative from observational transcriptomic studies and do not demonstrate causation, clinical outcomes, or direct therapeutic application.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
INTRODUCTION: Bipolar disorder (BD) is a major psychiatric illness with a high global burden, unclear pathophysiology, and limited biological markers, leaving diagnosis reliant on behavioral criteria. While there is an increasing number of individual transcriptomic studies investigating genes involved in BD, comprehensive cross-tissue meta-analyses remain lacking. METHODS: In this study, we conducted eight independent meta-analyses of differentially expressed genes (DEGs) across the whole brain, Brodmann area 9 (BA9), BA9 + BA46, and blood, integrating 19 publicly available postmortem brain datasets with 917 samples (386 BD patients, 531 controls) and six independent peripheral blood cohorts of 638 samples (316 BD, 322 controls). RESULTS: We identified enrichment of genes involved in mitochondrial bioenergetics and oxidative stress, as well as in synaptic structure, signaling, and neuroinflammatory pathways. These findings suggest coordinated disruption of neuronal metabolism and circuit function in BD. Additionally, we found several novel lncRNAs, miRNAs, and snoRNAs, including SNORD62B, SNORA70, and SNORA10, not previously linked to BD. DrugBank annotation highlighted pharmacologically actionable genes, including SST, P2RY12, and C3, underscoring the therapeutic relevance of our findings. CONCLUSION: Together, these results establish an integrated molecular framework of BD pathogenesis involving impaired inhibitory circuitry, mitochondrial dysfunction, neuroimmune dysregulation, and non-coding RNA networks, while providing candidate biomarkers and druggable targets, such as SST, to guide future mechanistic and therapeutic studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.